X0306 4 2015-05-04 0 0001607678 Viking Therapeutics, Inc. VKTX 0001614589 Dinerman Michael C/O VIKING THERAPEUTICS, INC. 11119 NORTH TORREY PINES ROAD, SUITE 50 SAN DIEGO CA 92037 0 1 0 0 Chief Operating Officer Common Stock, par value $0.00001 per share 2015-05-04 4 D 0 998250 D 576750 D Common Stock, par value $0.00001 per share 2015-05-04 4 A 0 105000 0.00 A 681750 D Common Stock, par value $0.00001 per share 2015-05-04 4 C 0 3642 A 685392 D Common Stock, par value $0.00001 per share 2015-05-04 4 F 0 8724 9.49 A 694116 D Stock Option (Right to Buy) 9.49 2015-05-04 4 A 0 45000 0.00 A 2015-05-04 2025-05-04 Common Stock 45000 45000 D Convertible Note due 2015 6.00 2015-05-04 4 C 0 21854.00 0.00 D Common Stock 3642 3642 D Of the shares repurchased by the Issuer, 901,216 shares were fully vested and 97,034 were subject to vesting. Shares were repurchased by the Issuer at a price of $0.00001 per share. Includes 56,091 shares of restricted stock that are subject to vesting, of which 11,214 will vest on May 26, 2015 and each month thereafter through and including August 26, 2015 and 11,235 which will vest on September 26, 2015. Represents a restricted stock award of common stock under the Issuer's 2014 Equity Incentive Plan. One third of the shares subject to the restricted stock award shall vest on each one year anniversary of the grant date of the award. The outstanding principal balance under the convertible note, plus all accrued and unpaid interest thereon, automatically converted into shares of common stock upon the closing of the Issuer's initial public offering at a conversion price equal to 75% of the price at which shares were sold to the public. The convertible note had no expiration date. Represents a restricted stock award of 20,186 shares of common stock granted under the Issuer's 2014 Equity Incentive Plan. All of the shares subject to the restricted stock award vested immediately upon grant. In order to satisfy certain tax withholding obligations, the Issuer repurchased 11,462 of these shares from the Reporting Person. 25% of the shares subject to the option were vested upon grant and 25% of the shares subject to the option will vest on each one year anniversary of the grant date. /s/ Michael Morneau, as Attorney-in-Fact 2015-05-06